Technology area: Biotechnology & Pharmaceuticals
26 pending office actions • 21 art units • 26 examiners • 0 of 26 (0%) have an AI response strategy ready • 19 patents granted in the last 365 days
Children’S Medical Center Corporation has 1 pending office action in the Medical Devices & Mechanical Engineering technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. ROBINSON, NICHOLAS A is the busiest examiner, managing the pending office action.
The prosecution is highly focused, with a distinct art unit and 1 distinct examiner involved in the company's current filings. Since ROBINSON, NICHOLAS A is the examiner for the 1 pending office action, the company's progress in the Medical Devices & Mechanical Engineering area depends on this individual's review. This concentration allows for a dedicated prosecution strategy but also means that the company's outcomes are tied to the specific tendencies of the examiner.
Practitioners should note that the pending office action represents the entirety of the company's active workload in this profile. The involvement of only a distinct art unit indicates that the subject matter is localized within a specific technical group. Successfully navigating the 1 pending office action will require a thorough understanding of the requirements set forth by ROBINSON, NICHOLAS A and the standards of the art unit involved.
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (8%) |
| §103 only | 12 (46%) |
| §102 only | 2 (8%) |
| §112 only | 2 (8%) |
| Double-patenting + other | 2 (8%) |
| Multi-statute (no §101) | 6 (23%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOAKES, SUZANNE MARIE | 1 | 73.4% | +18.3% |
| HUPCZEY, JR, RONALD JAMES | 1 | 64.8% | +22.3% |
| ZEMAN, ROBERT A | 1 | 54.2% | +27.9% |
| BUI, PHUONG T | 1 | 81.2% | +23.4% |
| EPSTEIN, TODD MATTHEW | 1 | 60.8% | +43.6% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.4% |
| BENAVIDES, JENNIFER ANN | 1 | 50.8% | +47.3% |
| DIETZ, NOE ROBERT | 1 | 0.0% | +0.0% |
| GHERBI, SUZETTE JAIME J | 1 | 85.1% | +8.7% |
| HORLICK, KENNETH R | 1 | 79.0% | +15.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030473 | ENGINEERING-DESIGN-BASED WORKFLOW FOR VALVE RECONSTRUCTION | GHERBI, SUZETTE JAIME J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17371017 | MYBPC3 POLYPEPTIDES AND USES THEREOF | DHAR, MATASHA | 107d overdue |
| 17422638 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | CREWS, JARET JAMES | 53d overdue |
| 18030467 | COMPUTATIONAL PLANNING OF SURGICAL RECONSTRUCTION | DIETZ, NOE ROBERT | 28d overdue |
| 19064858 | GTP CYCLOHYDROLASE-CLEAVING PROTEASES | NOAKES, SUZANNE MARIE | — |
| 18579325 | EXTRACHROMOSOMAL CIRCULAR DNA AS AN IMMUNOSTIMULANT AND BIOMARKER FOR DISEASE | BUI, PHUONG T | — |
| 18281540 | POLYSACCHARIDE ADJUVANTS FOR VIRUS VACCINES | CHEN, STACY BROWN | — |
| 18014901 | GUIDING BLOOD PRODUCT ADMINISTRATION TO MITIGATE BLEEDING RISK | FRITCHMAN, REBECCA M | — |
| 17486855 | ABCB5(+) STEM CELLS FOR TREATING OCULAR DISEASE | FOX, ALLISON M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278394 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | BENAVIDES, JENNIFER ANN | 27d |
| 18282215 | ENGINEERED BOTULINUM NEUROTOXIN A PROTEASE DOMAIN WITH IMPROVED EFFICACY | EPSTEIN, TODD MATTHEW | 82d |
| 19064858 | GTP CYCLOHYDROLASE-CLEAVING PROTEASES | NOAKES, SUZANNE MARIE | — |
| 18806000 | SUCTION ACTUATED ELECTROCAUTERY AND SUCTION DEVICE | HUPCZEY, JR, RONALD JAMES | — |
| 18799550 | PROTEIN ANTIGENS THAT PROVIDE PROTECTION AGAINST PNEUMOCOCCAL COLONIZATION AND/OR DISEASE | ZEMAN, ROBERT A | — |
| 18579325 | EXTRACHROMOSOMAL CIRCULAR DNA AS AN IMMUNOSTIMULANT AND BIOMARKER FOR DISEASE | BUI, PHUONG T | — |
| 18281540 | POLYSACCHARIDE ADJUVANTS FOR VIRUS VACCINES | CHEN, STACY BROWN | — |
| 18168131 | FORCE-CONTROLLED NANOSWITCH ASSAYS FOR SINGLE-MOLECULE DETECTION IN COMPLEX BIOLOGICAL FLUIDS | HORLICK, KENNETH R | — |
| Art Unit | Apps |
|---|---|
| 1633 | 3 |
| 1645 | 2 |
| 3771 | 2 |
| 1691 | 2 |
| 1653 | 1 |
| 3794 | 1 |
| 1663 | 1 |
| 1699 | 1 |
| 1672 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19064858 | GTP CYCLOHYDROLASE-CLEAVING PROTEASES | NOAKES, SUZANNE MARIE | 1653 | §102§112 | Non-Final OA | — | Pending | Feb 27, 2025 |
| 18806000 | SUCTION ACTUATED ELECTROCAUTERY AND SUCTION DEVICE | HUPCZEY, JR, RONALD JAMES | 3794 | §102Other | Final Rejection | — | Pending | Aug 15, 2024 |
| 18799550 | PROTEIN ANTIGENS THAT PROVIDE PROTECTION AGAINST PNEUMOCOCCAL COLONIZATION AND/OR DISEASE | ZEMAN, ROBERT A | 1645 | §103 | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18579325 | EXTRACHROMOSOMAL CIRCULAR DNA AS AN IMMUNOSTIMULANT AND BIOMARKER FOR DISEASE | BUI, PHUONG T | 1663 | §102§103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18282215 | ENGINEERED BOTULINUM NEUROTOXIN A PROTEASE DOMAIN WITH IMPROVED EFFICACY | EPSTEIN, TODD MATTHEW | 1699 | §102 | Non-Final OA | 82d | Pending | Sep 14, 2023 |
| 18281540 | POLYSACCHARIDE ADJUVANTS FOR VIRUS VACCINES | CHEN, STACY BROWN | 1672 | §102§103 | Non-Final OA | — | Pending | Sep 11, 2023 |
| 18278394 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | BENAVIDES, JENNIFER ANN | 1675 | §103Other | Final Rejection | 27d | Pending | Aug 22, 2023 |
| 18030467 | COMPUTATIONAL PLANNING OF SURGICAL RECONSTRUCTION | DIETZ, NOE ROBERT | 3791 | §103 | Final Rejection | 28d overdue | Pending | Apr 05, 2023 |
| 18030473 | ENGINEERING-DESIGN-BASED WORKFLOW FOR VALVE RECONSTRUCTION | GHERBI, SUZETTE JAIME J | 3774 | §103 | Non-Final OA | — | Pending | Apr 05, 2023 |
| 18168131 | FORCE-CONTROLLED NANOSWITCH ASSAYS FOR SINGLE-MOLECULE DETECTION IN COMPLEX BIOLOGICAL FLUIDS | HORLICK, KENNETH R | 1681 | §112DP | Non-Final OA | — | Pending | Feb 13, 2023 |
| 18014901 | GUIDING BLOOD PRODUCT ADMINISTRATION TO MITIGATE BLEEDING RISK | FRITCHMAN, REBECCA M | 1758 | §101§103§112 | Non-Final OA | — | Pending | Jan 06, 2023 |
| 17799418 | TAZ GENE OR ENZYME REPLACEMENT THERAPY | GU, QINHUA | 1633 | §103 | Non-Final OA | 24d overdue | Pending | Aug 12, 2022 |
| 17878406 | INTRACORPOREAL SUTURE TYING | JAFFRI, ZEHRA | 3771 | §103 | Final Rejection | 5d overdue | Pending | Aug 01, 2022 |
| 17759045 | IMMUNOLOGICALLY OPTIMIZED BOTULINUM TOXIN LIGHT CHAIN VARIANTS | DEVI, SARVAMANGALA | 1645 | §112 | Final Rejection | 36d overdue | Pending | Jul 19, 2022 |
| 17855719 | TISSUE FASTENING | SCHERBEL, TODD J | 3771 | §103 | Non-Final OA | 33d | Pending | Jun 30, 2022 |
| 17777659 | STIMULI THAT HYPERACTIVATE RESIDENT DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY | CHATTIN, AMY MARIE | 1643 | §103 | Final Rejection | 91d overdue | Pending | May 18, 2022 |
| 17769536 | METHODS FOR MULTI-FOCAL IMAGING FOR MOLECULAR PROFILING | CROW, ROBERT THOMAS | 1683 | §103§112DP | Non-Final OA | — | Pending | Apr 15, 2022 |
| 17635409 | LARGE SCALE PRODUCTION OF EXOSOME MIMETICS AND USES THEREOF | MEJIAS, SAMANTHA LEE | 1618 | §103 | Non-Final OA | 14d | Pending | Feb 15, 2022 |
| 17486855 | ABCB5(+) STEM CELLS FOR TREATING OCULAR DISEASE | FOX, ALLISON M | 1633 | §101§112 | Non-Final OA | — | Pending | Sep 27, 2021 |
| 17422638 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | CREWS, JARET JAMES | 1691 | §103§112 | Final Rejection | 53d overdue | Pending | Jul 13, 2021 |
| 17371017 | MYBPC3 POLYPEPTIDES AND USES THEREOF | DHAR, MATASHA | 1632 | §103§112 | Final Rejection | 107d overdue | Pending | Jul 08, 2021 |
| 17275266 | NANOPARTICLE FORMULATIONS AND METHODS OF THEIR USE | WAX, ROBERT A | 1615 | §103 | Non-Final OA | — | Pending | Mar 11, 2021 |
| 17053752 | MESENCHYMAL STROMAL CELL EXOSOME-TREATED MONOCYTES AND USES THEREOF | WESTON, ALYSSA G | 1633 | §102§103 | Non-Final OA | — | Pending | Nov 06, 2020 |
| 16979084 | COMPOSITIONS AND METHODS FOR MUTATIONS ASSOCIATED WITH SUDDEN UNEXPECTED DEATH IN PEDIATRICS | LEE, ANDREW P | 1691 | §103 | Non-Final OA | 128d overdue | Pending | Sep 08, 2020 |
| 16639474 | PURIFIED MESENCHYMAL STEM CELL EXOSOMES AND USES THEREOF | WEHBE, ANNE MARIE SABRINA | 1634 | §112 | Non-Final OA | — | Pending | Feb 14, 2020 |
| 16628162 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA | BEANE, RANDALL L | 1654 | §103 | Final Rejection | — | Pending | Jan 02, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChildren's Medical Center Corporation has 26 pending office actions as of October 2026, spread across 21 art units and 26 examiners.
Suzanne Marie Noakes has the most, with 1 of Children's Medical Center Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
